Bluefield Innovations

Bluefield Innovations Pursues Broadly Applicable Cancer Target

New York, NY and Baltimore, MD – January 4, 2018 – Bluefield Innovations, a collaboration between Deerfield Management and The Johns Hopkins University to catalyze early stage therapeutic development, announced today the acceptance and funding of its first project. The target, the enzyme RNA polymerase I (Pol I), is implicated in many forms of cancer.

Originating in the lab of Dr. Marikki Laiho, the Willard and Lillian Hackerman Professor of Radiation Oncology and director of the Division of Molecular Radiation Sciences at the Johns Hopkins University School of Medicine, the discovery illustrates how cancer cells disproportionately rely on the Pol I cellular pathway when compared to normal cells. Dr. Laiho’s research indicates that interfering with this pathway kills cancer cells while causing little harm to normal cells. The acceptance of this project comes just two months after the launch of Bluefield Innovations.

“We are excited to accept Dr. Laiho’s project into Bluefield Innovations and show our commitment to the goal of advancing promising research projects,” says James Flynn, Managing Partner at Deerfield Management.

Bluefield will provide scientific, financial and operational support to Dr. Laiho’s research, enabling her team to identify the clinical lead molecule and to move that candidate toward human clinical trials. Ultimately, this support could lead to the development of a first-in-class small molecule drug.

“I truly appreciate the opportunity to align with a collaborator that shares the same mindset and goals surrounding early stage research targets,” Dr. Laiho says. “Bluefield understands that new targets and first-in-class molecules require a higher level of due diligence and with that, they provide the expertise to support the extensive ground work required for the IND process.” A joint steering committee consisting of representatives from Deerfield and Johns Hopkins selected Dr. Laiho’s research to receive the first round of support from Bluefield. The initial five-year term of Bluefield Innovations will provide support and funding to approximately a dozen Johns Hopkins faculty and researchers. A call for applications will take place in the first quarter of 2018.

“Bluefield Innovations provides a valuable avenue for Johns Hopkins researchers to unleash the potential of their promising work,” says Dr. William Nelson, professor of oncology and director of the Johns Hopkins Sidney Kimmel Cancer Center. “Dr. Laiho’s research may prove to be a transformational cancer treatment. We’re excited that Bluefield has provided her an opportunity to accelerate its development and commercialization.”

About Bluefield Innovations

Bluefield Innovations is an innovative collaboration between The Johns Hopkins University and Deerfield Management that is dedicated to navigating the complexities of scientific advancement from concept to commercialization. Funded by Deerfield Management, Bluefield Innovations is providing up to $65 million over five years to support the commercialization of early stage therapeutic research at Johns Hopkins.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com.

Contacts
Deerfield Management Company
Karen Heidelberger, 212-551-1600
karenh@deerfield.com

Deerfield and The Johns Hopkins University Announce Collaboration to Catalyze Early Stage Therapeutic Research

Posted on: January 31, 2018

New York, NY and Baltimore, MD – November 16, 2017 – Deerfield Management and The Johns Hopkins University announced today the creation of Bluefield Innovations, a collaboration designed to catalyze the development of early stage therapeutics. Funded by Deerfield, an investment management firm committed to advancing healthcare, Bluefield Innovations will provide up to $65 million in initial funding over five years to support the commercialization of early stage therapeutic research at Johns Hopkins, with additional funding available to advance research showing strong commercial potential.

A joint steering committee will identify the research that Bluefield will support through the preclinical development process — including basic research, proof of concept, target selection and investigational new drug (IND) enabling studies designed to qualify a candidate to enter into human clinical trials. Research developed within Bluefield will either be licensed to third parties or spun out into new companies. Funding for companies supported by Bluefield may include capital from Deerfield.

“We are proud and excited to be collaborating with Johns Hopkins, a premier institution with world-class scientists dedicated to pushing the boundaries of discovery to transform healthcare,” stated James Flynn, Managing Partner at Deerfield Management. “Further, the development expertise and scientific leadership resident at Johns Hopkins Drug Discovery Program is a tremendous asset in enabling Bluefield to move the innovations of Hopkins’ scientists forward toward their therapeutic applications.”

Combining the respective strengths of each organization — Johns Hopkins’ scientific discovery expertise and Deerfield’s drug development, operational and financial support — enables Bluefield to reduce the financial and developmental risk associated with early stage novel projects.

“For more than 125 years, Johns Hopkins has been at the forefront of research and medical innovation. As we expand this tradition, collaborations with industry will help us more efficiently move groundbreaking technologies to market,” said Ronald J. Daniels, president of The Johns Hopkins University. “Our relationship with Deerfield will provide a fully funded and professionally supported avenue for Johns Hopkins researchers to deliver on the potential of their promising work.”